135 related articles for article (PubMed ID: 24946238)
1. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.
Nagano K; Maeda Y; Kanasaki S; Watanabe T; Yamashita T; Inoue M; Higashisaka K; Yoshioka Y; Abe Y; Mukai Y; Kamada H; Tsutsumi Y; Tsunoda S
J Control Release; 2014 Sep; 189():72-9. PubMed ID: 24946238
[TBL] [Abstract][Full Text] [Related]
2. [Development of a Fundamental Technology to Seek Drug Targets, and Its Application to Cancer Targeting Therapy].
Nagano K; Higashisaka K; Tsunoda SI; Tsutsumi Y
Yakugaku Zasshi; 2018; 138(7):903-909. PubMed ID: 29962467
[TBL] [Abstract][Full Text] [Related]
3. Eph receptor A10 has a potential as a target for a prostate cancer therapy.
Nagano K; Yamashita T; Inoue M; Higashisaka K; Yoshioka Y; Abe Y; Mukai Y; Kamada H; Tsutsumi Y; Tsunoda S
Biochem Biophys Res Commun; 2014 Jul; 450(1):545-9. PubMed ID: 24924629
[TBL] [Abstract][Full Text] [Related]
4. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.
Cha JH; Chan LC; Wang YN; Chu YY; Wang CH; Lee HH; Xia W; Shyu WC; Liu SP; Yao J; Chang CW; Cheng FR; Liu J; Lim SO; Hsu JL; Yang WH; Hortobagyi GN; Lin C; Yang L; Yu D; Jeng LB; Hung MC
J Biol Chem; 2022 Apr; 298(4):101817. PubMed ID: 35278434
[TBL] [Abstract][Full Text] [Related]
5. [Challenge to the Development of Molecular Targeted Therapy against a Novel Target Candidate Identified by Antibody Proteomics Technology].
Nagano K
Yakugaku Zasshi; 2016; 136(2):145-9. PubMed ID: 26831784
[TBL] [Abstract][Full Text] [Related]
6. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
Taki S; Kamada H; Inoue M; Nagano K; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
PLoS One; 2015; 10(12):e0144712. PubMed ID: 26678395
[TBL] [Abstract][Full Text] [Related]
7. EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6-expressing MDA-MB-231 Cells.
Johnson C; Segovia B; Kandpal RP
Cancer Genomics Proteomics; 2016 09-10; 13(5):359-68. PubMed ID: 27566654
[TBL] [Abstract][Full Text] [Related]
8. Stem-like Cells from Invasive Breast Carcinoma Cell Line MDA-MB-231 Express a Distinct Set of Eph Receptors and Ephrin Ligands.
Lucero M; Thind J; Sandoval J; Senaati S; Jimenez B; Kandpal RP
Cancer Genomics Proteomics; 2020; 17(6):729-738. PubMed ID: 33099474
[TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3.
Kamada H; Taki S; Nagano K; Inoue M; Ando D; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
Biochem Biophys Res Commun; 2015 Jan; 456(4):908-12. PubMed ID: 25528586
[TBL] [Abstract][Full Text] [Related]
10. Ephrin A4-ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells.
Chen YL; Yen YC; Jang CW; Wang SH; Huang HT; Chen CH; Hsiao JR; Chang JY; Chen YW
Sci Rep; 2021 Jan; 11(1):644. PubMed ID: 33436772
[TBL] [Abstract][Full Text] [Related]
11. Artesunate-induced Cellular Effects Are Mediated by Specific EPH Receptors and Ephrin Ligands in Breast Carcinoma Cells.
Zadeh T; Lucero M; Kandpal RP
Cancer Genomics Proteomics; 2022; 19(1):19-26. PubMed ID: 34949656
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.
Wang K; Xie S; Ren Y; Xia H; Zhang X; He J
Oncol Rep; 2012 Jun; 27(6):1981-9. PubMed ID: 22446691
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].
Wang K; Xie SM; He JJ; Ren Y; Xia HB; Zhang XW
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1812-8. PubMed ID: 22126756
[TBL] [Abstract][Full Text] [Related]
14. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
15. ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro.
Chen Y; Zou H; Yang LY; Li Y; Wang L; Hao Y; Yang JL
Asian Pac J Cancer Prev; 2012; 13(5):2385-92. PubMed ID: 22901226
[TBL] [Abstract][Full Text] [Related]
16. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
[TBL] [Abstract][Full Text] [Related]
17. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells.
Kim SY; Lee IS; Moon A
Chem Biol Interact; 2013 May; 203(3):565-72. PubMed ID: 23562496
[TBL] [Abstract][Full Text] [Related]
18. The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells.
Shin WS; Park MK; Lee YH; Kim KW; Lee H; Lee ST
Cancer Sci; 2020 Sep; 111(9):3292-3302. PubMed ID: 32644283
[TBL] [Abstract][Full Text] [Related]
19. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
20. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
